<DOC>
	<DOCNO>NCT00778232</DOCNO>
	<brief_summary>This study compare relative bioavailability ( rate extent absorption ) Gabapentin tablets 800 mg Ranbaxy Laboratories Limited Neurontin ® 800 mg tablet Parke Davis Pharmaceuticals Ltd . Distributed Parke-Davis , division Warner-Lambert Co. follow single oral dose ( 1x800 mg tablet ) healthy adult volunteer non-fasting condition .</brief_summary>
	<brief_title>Bioequivalence Study Gabapentin 800 mg Tablets Under Fed Conditions</brief_title>
	<detailed_description>A single oral dose test reference product administer 22 healthy adult human volunteer two separate occasion non-fasting condition least 7 day washout dos . Food fluid intake control confinement period . Twenty two ( 22 ) healthy adult human volunteer ( 12 male 10 female ) enrol study . All twenty two ( 22 ) subject successfully complete clinical portion study</detailed_description>
	<mesh_term>Gabapentin</mesh_term>
	<mesh_term>gamma-Aminobutyric Acid</mesh_term>
	<criteria>1 . All volunteer select study healthy men woman 18 year age old time dose 2 . The weight exceed ± 20 % height body frame per desirable weight adult 1983 Metropolitan height weight table 3 . If female Of Child bear potential , practice acceptable method birth control duration study judge investigator ( ) , condom , foam , jelly , diaphragm , intrauterine device ( IUD ) , abstinence ; Is postmenopausal least 1 year ; Is surgically sterile ( bilateral tubal ligation , bilateral oophorectomy , hysterectomy ) 1. volunteer recent history drug alcohol addiction abuse 2 . Volunteers presence clinically significant disorder involve cardiovascular , respiratory , renal , gastrointestinal , immunologic , hematologic , endocrine , neurologic system ( ) psychiatric disease ( determined clinical investigator ) 3 . Volunteers whose clinical laboratory test value outside accept reference range confirm reexamination deem clinically significant 4 . Volunteers demonstrate positive hepatitis B surface antigen screen reactive HIV antibody screen 5 . Volunteers demonstrate positive drug abuse screen screen study 6 . Female volunteer demonstrate positive pregnancy screen 7 . Female volunteer currently breast feed 8 . Volunteers history allergic response ( ) Gabapentin related drug 9 . Volunteers history clinically significant allergy include drug allergy 10 . Volunteers clinically significant illness 4 week prior period I dose ( determined clinical investigator ) 11 . Volunteers currently use tobacco product 12 . Volunteers take drug know induce inhibit hepatic drug metabolism 28 day prior period I dose 13 . Volunteers report donate great 150 mL blood within 30 day prior period I dose . All subject advise donate blood four week complete study 14 . Volunteers donate plasma ( eg . Plasmapheresis ) within 14 day prior period I dose . All subject advise donate plasma four week complete study 15 . Volunteers report receive investigational drug within 30 day prior period I dose 16 . Volunteers report take systemic prescription medication 14 day prior period I dose .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2008</verification_date>
	<keyword>Bioequivalence Gabapentin tablets 800 mg feed condition</keyword>
</DOC>